Johnson and Johnson Presents New Heart Ablation Data
The company showcased positive clinical results for two pulsed field ablation devices in South Korea.
Updated on Oct. 23, 2026 in Heart Disease
Live Poll
Do you trust that new medical devices generally lead to better long-term health outcomes?
Johnson and Johnson recently presented clinical data on its Varipure and Omnypulse devices for treating atrial fibrillation at the Asia Pacific Heart Rhythm Society 2026 annual meeting. The study findings highlight significant procedural success rates using pulsed field ablation technology.
Why it matters
These results provide insight into the efficacy of newer ablation technologies for patients suffering from abnormal heart rhythms. The data helps clinicians evaluate the long-term potential of these specific medical devices in cardiology.
The Varipure study recorded a 100% acute procedural success rate across 225 patients. Meanwhile, the Omnypulse trial reported that 82.5% of 136 patients remained free of abnormal heart rhythm recurrence after a 12-month monitoring period.
The players
Johnson and Johnson
This global medical technology and pharmaceutical company operates a major campus in Irvine and maintains its corporate headquarters in New Jersey.
The details
The devices utilize pulsed field ablation, an approach designed to treat atrial fibrillation by isolating the tissue responsible for erratic electrical signals. Researchers evaluated these treatments based on both immediate procedural success and long-term rhythm stability.
Timeline
The Asia Pacific Heart Rhythm Society annual meeting took place in 2026.
Patients in the Omnypulse study underwent a 12-month post-treatment monitoring period.
Health Landscape
This study aligns with the broader research-sharing goals of the Asia Pacific Heart Rhythm Society annual meeting. It represents a shift toward evaluating pulsed field ablation as a standard treatment option for atrial fibrillation in the global cardiology market.
Patients with atrial fibrillation may eventually gain access to more effective treatment options as these devices move through clinical validation. These advancements could offer new ways to manage heart rhythm stability compared to legacy procedures.
The takeaway
These findings underscore the ongoing evolution of medical technology in addressing common cardiac rhythm disorders. Patients and providers should discuss how these new ablation techniques compare to traditional interventions for long-term health management.
Further reading
For more information on current treatment trends, see our Heart Disease section.
Source note: This article includes information reported by Orange County Business Journal.
Live Poll
Do you trust that new medical devices generally lead to better long-term health outcomes?
